Retatrutide, by Soma Corp., is receiving increasing attention as a potential therapy for metabolic management . This innovative drug merges the properties of a GLP-1 receptor stimulant and a GIP receptor activator , intended to not only promote reduced body fat but also improve associated metabolic issues . Early human studies have indicated impres